All In Biotech

Drug Trial Radar · NCT05633654

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,514 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,514

Planned (sponsor's estimate)

Start

Dec 12, 2022

Primary completion

Jun 2027

Study completion Aug 2031

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Alliance Foundation Trials, LLC.; NSABP Foundation Inc; GBG Forschungs GmbH
First posted
Dec 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • Sacituzumab govitecan-hziy (SG)Drug

    Administered intravenously

  • PembrolizumabDrug

    Administered intravenously

  • CapecitabineDrug

    Tablets administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (iDFS)Time frame: Up to 60 months

Locations

378 sites in 12 countries. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama · Recruiting

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Palo Verde Hematology Oncology

    Glendale, Arizona · Recruiting

  • Mayo Clinic Hospital

    Phoenix, Arizona · Withdrawn

  • Arizona Oncology Associates

    Prescott Valley, Arizona · Withdrawn

  • Alta Bates Summit Medical Center

    Berkeley, California · Recruiting

  • Community Cancer Institute

    Clovis, California · Withdrawn

  • PIH Health Whittier Hospital

    Downey, California · Recruiting

  • Compassionate Cancer Care Medical Group - Inc

    Fountain Valley, California · Active not recruiting

  • Los Angeles Cancer Network

    Los Angeles, California · Active not recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Withdrawn

  • Cedars-Sinai Cancer at Beverly Hills

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • Emad Ibrahim, MD, INC

    Redlands, California · Withdrawn

  • Sutter Institute for Medical Research

    Sacramento, California · Recruiting

  • City of Hope (Duarte)

    San Francisco, California · Recruiting

  • UCSF Medical Center

    San Francisco, California · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Recruiting

  • Stockton Hematology Oncology Medical Group

    Stockton, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Withdrawn

  • Norwalk Hospital

    Danbury, Connecticut · Withdrawn

  • Stamford Hospital

    Stamford, Connecticut · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Morton Plant Hospital - Bay Care

    Clearwater, Florida · Withdrawn

  • University of Florida

    Gainesville, Florida · Withdrawn

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Recruiting

  • Jupiter Medical Center

    Jupiter, Florida · Recruiting

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida · Recruiting

  • Midland Florida Clinical Research Center, L

    Orange City, Florida · Withdrawn

  • Orlando Health

    Orlando, Florida · Active not recruiting

  • Cancer Care Centers of Brevard, Inc

    Palm Bay, Florida · Recruiting

  • Memorial Healthcare System

    Pembroke Pines, Florida · Recruiting

  • Sacred Heart Medical Oncology Group

    Pensacola, Florida · Withdrawn

  • Sylvester Comprehensive Cancer Center

    Plantation, Florida · Recruiting

  • Cleveland Clinic Florida, Martin North Hospital

    Stuart, Florida · Withdrawn

  • St. Joseph's Hospital

    Tampa, Florida · Withdrawn

  • Weston Hospital

    Weston, Florida · Withdrawn

  • University Cancer & Blood Center, LLC.

    Athens, Georgia · Recruiting

Showing 40 of 378 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.